Phase 2 N=18 Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose of Bendamustine — 80 mg/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation
PIK3CA-Related Overgrowth Spectrum (PROS) · Growth Disorder · Genetics
Primary: Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA — 7.9; 4.8; 0.71; 6.5 mean percentage change in tissue volume
Phase 2 N=295 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Hyperkalemia · Resistant Hypertension
Primary: Number of Participants Remaining on Spironolactone at Week 12 — 126; 98 Participants — p=<0.0001
Phase 2 N=85 A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
High-risk Smoldering Multiple Myeloma
Primary: One-Year Progression-Free Survival (PFS) Rate — 84.5; 74.4 Percentage of participants
Phase 2 N=80 Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma
Asthma
Primary: Trough Forced Expiratoty Volume in 1 Second (FEV1) — 0.171; 0.212 L
Phase 2 N=14 Ketamine in Adolescents With Treatment-Resistant Depression
Major Depressive Disorder
Primary: Number of Responders Measured by Clinical Global Impression (CGI) — 5 Participants
Phase 2 N=33 A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
Community-acquired Pneumonia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 2; 4; 3 Participants
Phase 2 N=21 Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Depression · Major Depressive Disorder
Primary: Change in Hamilton Depression Rating Scale HDRS-21 — 5.5; 2.8 score on a scale — p=<0.05
Phase 2 N=135 A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
Coronary Heart Disease
Primary: Absolute Change From Baseline in HDL-C — 12.76; 0.50 mg/dL
Phase 2 N=59 Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · KIT Positive
Primary: Objective Response Rate (ORR) — 0; 5; 16; 8 Participants
Phase 2 N=118 Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Breast Cancer
Primary: Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 6; 3; 3 Participants
Phase 2 N=18 Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
Fabry Disease
Primary: Adverse Events — 54; 11; 29; 14 adverse events
Phase 2 N=56 Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Pediatric Growth Hormone Deficiency
Primary: Annual Height Velocity — 10.4; 11.0; 11.9; 12.5 cm/year
Phase 2 N=15 Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Cardiorespiratory Fitness — 4.1; 4.0; 5.1; 4.5 ml/kg/min
Phase 2 N=65 Alzheimer's Disease: Potential Benefit of Isoflavones
Alzheimer's Disease
Primary: Cognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min — 21.5; 25.7 number of words generated per minute